Zobrazeno 1 - 10
of 344
pro vyhledávání: '"Mafalda Oliveira"'
Autor:
Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, Olga Martínez-Sáez, Juan Miguel Cejalvo, Mireia Margelí, Pablo Tolosa, Francisco Javier Salvador-Bofill, Josefina Cruz, Blanca González-Farré, Esther Sanfeliu, Andreu Òdena, Violeta Serra, Francisco Pardo, Ana María Luna Barrera, Miriam Arumi, Juan Antonio Guerra, Guillermo Villacampa, Rodrigo Sánchez-Bayona, Eva Ciruelos, Martín Espinosa-Bravo, Yann Izarzugaza, Patricia Galván, Judith Matito, Sonia Pernas, Maria Vidal, Anu Santhanagopal, Dalila Sellami, Stephen Esker, Pang-Dian Fan, Fumitaka Suto, Ana Vivancos, Tomás Pascual, Aleix Prat, Mafalda Oliveira
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Patritumab deruxtecan (HER3-DXd) exhibits promising efficacy in breast cancer, with its activity not directly correlated to baseline ERBB3/HER3 levels. This research investigates the genetic factors affecting HER3-DXd’s response in women w
Externí odkaz:
https://doaj.org/article/7c7d4486147e4021ad5651e0e2b54a88
Autor:
François Panet, Andri Papakonstantinou, Maria Borrell, Joan Vivancos, Ana Vivancos, Mafalda Oliveira
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-15 (2024)
Abstract Circulating free tumor DNA (ctDNA) analysis is gaining popularity in precision oncology, particularly in metastatic breast cancer, as it provides non-invasive, real-time tumor information to complement tissue biopsies, allowing for tailored
Externí odkaz:
https://doaj.org/article/0661ec00322d47cd90d227632acee1de
Autor:
Tomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, Adam D. Pfefferle, Nuria Chic, Fara Brasó-Maristany, Blanca Gonzàlez-Farré, Laia Paré, Guillermo Villacampa, Cristina Saura, Cristina Hernando, Montserrat Muñoz, Patricia Galván, Xavier Gonzàlez-Farré, Mafalda Oliveira, Miguel Gil-Gil, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá, Aleix Prat, Charles M. Perou
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-11 (2024)
Abstract In this study, we performed genomic analyses of cell cycle and tumor microenvironment changes during and after ribociclib and letrozole or chemotherapy in the CORALLEEN trial. 106 women with untreated PAM50-defined Luminal B early breast can
Externí odkaz:
https://doaj.org/article/3f189cf1ef8a4f74a950d11ff22079b9
Autor:
Aleix Prat, Fara Brasó-Maristany, Olga Martínez-Sáez, Esther Sanfeliu, Youli Xia, Meritxell Bellet, Patricia Galván, Débora Martínez, Tomás Pascual, Mercedes Marín-Aguilera, Anna Rodríguez, Nuria Chic, Barbara Adamo, Laia Paré, Maria Vidal, Mireia Margelí, Ester Ballana, Marina Gómez-Rey, Mafalda Oliveira, Eudald Felip, Judit Matito, Rodrigo Sánchez-Bayona, Anna Suñol, Cristina Saura, Eva Ciruelos, Pablo Tolosa, Montserrat Muñoz, Blanca González-Farré, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, Ana Vivancos
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-16 (2023)
Plasma ctDNA is a promising method to determine patient outcome in multiple cancer types. Here, the authors use shallow WGS to create machine learning signatures to identify tumor phenotypes and predict therapy response in patients with metastatic br
Externí odkaz:
https://doaj.org/article/3f12bbd8bddf4a1d9f66456aec50f23c
Autor:
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina Viaplana, Javier Hernández, Faye Su, Kui Lin, Robert B. Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C. Turner, Aleix Prat, Paolo Nuciforo, Rodrigo Dienstmann, Chandra S. Verma, Nuria Lopez-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-20 (2022)
CDK4/6 inhibitor resistance is common in breast cancer. Here, the authors show that p16 overexpression may be linked to reduced efficacy of CDK4/6 inhibition, and show that the combination with PI3K inhibitors may increase anti-tumour effects.
Externí odkaz:
https://doaj.org/article/c3a330e420d34dc992aab0ec2b80986a
Autor:
Rubén Olivera-Salguero, Elia Seguí, Juan Miguel Cejalvo, Mafalda Oliveira, Pablo Tolosa, Maria Vidal, Marcos Malumbres, Joaquín Gavilá, Cristina Saura, Sonia Pernas, Rafael López, Mireia Margelí, Judith Balmaña, Montserrat Muñoz, Isabel Blancas, Valentina Boni, Eva Ciruelos, Elena Galve, Antonia Perelló, Rodrigo Sánchez-Bayona, Susana de la Cruz, Miguel de la Hoya, Patricia Galván, Esther Sanfeliu, Blanca Gonzalez-Farre, Valeria Sirenko, Aura Blanch-Torras, Jordi Canes, Helena Masanas, Rosa Olmos, Margarita Forns, Aleix Prat, Ana Casas, Tomás Pascual
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundMetastatic breast cancer (mBC) causes nearly all BC-related deaths. Next-generation sequencing (NGS) technologies allow for the application of personalized medicine using targeted therapies that could improve patients’ outcomes. However,
Externí odkaz:
https://doaj.org/article/824e6c3277784295a0300733bf18032a
Autor:
Ana Teixeira-Vaz, José Afonso Rocha, Mafalda Oliveira, Tiago Simões-Moreira, David Almeida E Reis, Ana Isabel Silva, José Artur Paiva
Publikováno v:
PLoS ONE, Vol 18, Iss 6, p e0284597 (2023)
PurposeTo analyze the long-term consequences of critical COVID-19, regarding physical, mental, cognitive and functional impairments, and to describe its evolution through time.MethodsProspective cohort study, with consecutive inclusion of patients ad
Externí odkaz:
https://doaj.org/article/d4dd6cd683a548c68cbee146b61bfa91
Autor:
Tiago Pimenta, Helena Tavares, João Ramos, Mafalda Oliveira, David Reis, Hugo Amorim, Afonso Rocha
Publikováno v:
Revista Portuguesa de Cardiologia, Vol 40, Iss 12, Pp 957-964 (2021)
Introduction and objectives: During the COVID-19 pandemic, among the safety measures adopted, use of facemasks during exercise training sessions in cardiac rehabilitation programs raised concerns regarding possible detrimental effects on exercise cap
Externí odkaz:
https://doaj.org/article/fb80c45b560e48a3bf12ae29bd50f873
Autor:
Tomás Pascual, Mafalda Oliveira, Patricia Villagrasa, Vanesa Ortega, Laia Paré, Begoña Bermejo, Serafín Morales, Kepa Amillano, Rafael López, Patricia Galván, Jordi Canes, Fernando Salvador, Paolo Nuciforo, Isabel T. Rubio, Antonio Llombart-Cussac, Serena Di Cosimo, José Baselga, Nadia Harbeck, Aleix Prat, Javier Cortés
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-11 (2021)
Abstract Eribulin prolongs overall survival in patients with pre-treated advanced breast cancer. However, no biomarker exists to prospectively select patients who will benefit the most from this drug. SOLTI-1007-NeoEribulin is a phase II, open-label,
Externí odkaz:
https://doaj.org/article/41c7b00b4fff4204abca055bdf4c6649
Autor:
Luis Manso, Cristina Hernando, María Galán, Mafalda Oliveira, Miguel A. Cabrera, Raquel Bratos, César A. Rodríguez, Manuel Ruiz-Borrego, Salvador Blanch, Antonio Llombart-Cussac, Juan I. Delgado-Mingorance, Iñaki Álvarez-Busto, Isabel Gallegos, Lucía González-Cortijo, Serafín Morales, Elena Aguirre, Blanca A. Hernando, Ana Ballesteros, José E. Alés-Martínez, Cristina Reboredo, Amparo Oltra, María González-Cao, Marta Santisteban, Diego Malón, Isabel Echeverría, Elisa García-Garre, Estela Vega, Sònia Servitja, Raquel Andrés, Carlos E. Robles, Rafael López, Elena Galve, María J. Echarri, Marta Legeren, Fernando Moreno
Publikováno v:
Breast, Vol 54, Iss , Pp 286-292 (2020)
Background: This study evaluated efficacy and safety of palbociclib, a CDK4/6 inhibitor, in heavily-pretreated hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) patients during
Externí odkaz:
https://doaj.org/article/79a375e0252b436e8ea177a9f4f57a3e